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Abstract 
Background: The trophic, anti-apoptotic and regenerative effects of bone marrow mesenchymal stromal cells (MSC) 
may reduce neuronal cell loss in neurodegenerative disorders.
Methods: We used MSC as a novel candidate therapeutic tool in a pilot phase-I study for patients affected by 
progressive supranuclear palsy (PSP), a rare, severe and no-option form of Parkinsonism. Five patients received the 
cells by infusion into the cerebral arteries. Effects were assessed using the best available motor function rating scales 
(UPDRS, Hoehn and Yahr, PSP rating scale), as well as neuropsychological assessments, gait analysis and brain imaging 
before and after cell administration.
Results: One year after cell infusion, all treated patients were alive, except one, who died 9 months after the infusion 
for reasons not related to cell administration or to disease progression (accidental fall). In all treated patients motor 
function rating scales remained stable for at least six-months during the one-year follow-up.
Conclusions: We have demonstrated for the first time that MSC administration is feasible in subjects with PSP. In 
these patients, in whom deterioration of motor function is invariably rapid, we recorded clinical stabilization for at 
least 6 months. These encouraging results pave the way to the next randomized, placebo-controlled phase-II study 
that will definitively provide information on the efficacy of this innovative approach.
Trial registration ClinicalTrials.gov NCT01824121
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Background
Progressive supranuclear palsy (PSP), Steele–Richard-
son–Olszewsky syndrome (SR) type, is a progressive 
neurodegenerative disorder belonging to the group of 
taupathies, with motor, cognitive and behavioral symp-
toms. Its prevalence is about 6.5 cases per 100,000 peo-
ple and its incidence is about 5.3 new cases every 100,000 
people [1–3]. Although distinctive signs of PSP may 
appear already within the first 2  years of disease after 
onset, its clinical heterogeneity makes early diagnosis a 
challenge [4–6] and no reliable biomarkers are available. 
Therefore postmortem neuropathology is the diagnostic 
gold standard of PSP [7, 8]. Motor symptoms include gait 
disturbances, early onset of postural instability, backward 
falls, axial rigidity and restriction of vertical eye move-
ments [9]. Personality changes and cognitive impairment 
are other frequent invalidating symptoms [10]. Quality 
of life deteriorates rapidly and patients are confined to 
a wheelchair a few years after the onset of disease [11]. 
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Disease duration is generally no longer than 9  years [4, 
10, 12, 13]. Aspiration pneumonia and respiratory failure 
are frequent causes of death [14]. PSP has all the nega-
tive features of the most severe neurodegenerative disor-
ders: its etiology is unknown, it is invariably progressive, 
it does not respond to any available therapy and it brings 
a huge human and economic burden to society. Despite 
healthy neural cell replacement is the ideal objective 
of any curative therapy for PSP, as in many other neu-
rodegenerative disorders, up to now no approach can 
efficiently achieve this goal. Therefore, even treatment 
that could reduce neural cell loss and stabilize clinical 
symptoms would be a significant breakthrough in this 
field. The use of several new drugs, such as davunetide, 
a tau-directed therapeutic agent, and donezepil, failed to 
exert beneficial effects in PSP patients [15]. Only slight 
improvement was achieved with coenzyme Q10 [16]. On 
the other hand, both preclinical in vitro investigations as 
well as preliminary clinical studies have shown that bone 
marrow (BM) derived mesenchymal stromal cells (MSC) 
may offer a new strategy for several neurodegenerative 
disorders [17–19]. The biological hypothesis underly-
ing this approach is that MSC can exert neuroprotective 
effects by reducing cell apoptosis and neural cell loss [17]. 
We specifically define in our work MSC as mesenchy-
mal stromal cells since they completely fulfil the minimal 
requirements set by ISCT for mesenchymal stromal cells 
[18], while they only partially comply with the definition 
of stem cells [19]. With all this in mind and with no inten-
tion of actually replacing diseased neurons, we conceived 
a phase I study to test the safety of MSC intra-arterial 
infusion, as well as its effects in slowing down the rate of 
progression of the disease in PSP patients. We followed 
up the enrolled patients for 1  year, with the best avail-
able validated clinical rating scales for the assessment of 
Parkinsonism, neuroimaging procedures and an auto-
mated biomechanical evaluation. In the present report 
we describe the one-year follow-up results obtained in 
the first five PSP patients treated with autologous MSC.
Methods
Protocol approval, patient screening and cell 
manufacturing
The protocol was authorized by the local Ethics Com-
mittee of Fondazione IRCCS Cà Granda Ospedale 
Maggiore Policlinico (Italy), by the national competent 
authority for phase-I cell therapy at the National Health 
Institute (Istituto Superiore di Sanità) and approved by 
the Italian Medicines Agency (Agenzia Italiana del Far-
maco, AIFA). The trial is registered at ClinicalTrials.gov 
(NCT01824121). All patients gave their written informed 
consent. A detailed description of the study design, inclu-
sion and exclusion criteria, BM collection, MSC isolation 
and administration along with clinical (motor and neu-
ropsychological) and neuroimaging assessments have 
been previously reported [20]. In order to efficiently 
select the patients to be treated in the clinical trial, a 
pre-screening procedure was implemented. The patients 
who met the inclusion/exclusion criteria were therefore 
enrolled in a pre-clinical, validation study and underwent 
bone marrow aspiration to test the ability of their BM to 
give rise to MSC with the due quantitative and qualitative 
characteristics. In particular, the following specifications 
were set up to classify MSC cultures as compliant and 
therefore proceed towards expanding them for clinical 
use: (a) ≥1-fold expansion between passage 0 and 1 and 
between passage 1 and 2; (b) normal karyotype at passage 
0, 1 and 2.
This validation study was implemented because there 
is sporadic evidence that MSC from patients affected by 
neurological diseases might differ somehow from those 
generated from normal healthy donors [21]. In this way 
we ensured that the patients were treated only with 
cells that could be identified as standard MSC comply-
ing with the universally recognized characteristics [18]. 
A maximum of 30 mL of BM was harvested. All the cell 
preparations passed the quality controls following good 
manufacturing practices (GMP) rules.
Clinical and neuropsychological assessment
The patients underwent neurological examinations to 
assess motor function using the following scales: uni-
fied Parkinson’s disease rating scale [22] (UPDRS part-
III, motor score), Hoehn and Yahr staging [23] (H&Y), 
PSP rating scale [12] (PSP-RS). These tests, together 
with mini mental state evaluation (MMSE, according 
to Folstein et  al. [24]) were assessed at baseline and at 
each follow-up point (1, 3, 6 and 12  months after cell 
administration). The clinical conditions were classified 
as “stable” when the UPDRS and PSP-RS scores had not 
diminished by more than 30  % compared to baseline 
and the H&Y staging did not change at the defined time 
point.
Neuroimaging
All patients underwent longitudinal neuroimaging 
assessments, using brain magnetic resonance imaging 
(MRI) (baseline, 24 h after cell administration and after 
1  year), striatal dopamine transporter single photon 
emission computed tomography (SPECT) and positron 
emission tomography (PET) (both at baseline and after 
12  months). Tropanic tracers labeled with Iodine-123 
(FP-CIT) and 18F-Fluoro-2-deoxyglucose (Beta-CIT) 
were used for SPECT imaging and for PET/TC imag-
ing, respectively. For SPECT, intravenous administration 
of 110–140  MBq of [123I] FP-CIT (Datscan, GE-Health, 
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Amersham, UK) was performed 30–40  min after thy-
roid blockade (10–15  mg of Lugol solution per os) in 
all patients. The analysis was performed as already 
described [25]. A volumetric template of grey matter ana-
tomic distribution, generated from the Montreal Neu-
rological Institute MRI single participant brain atlas by 
applying a macroscopic anatomical method (automated 
anatomic labelling), was reoriented and reformatted to 
obtain a 2.64-cm-thick reference section. A template of 
eight irregular regions of interest (ROIs) was manually 
drawn on this section to assess the anatomical extent 
of striatal and occipital structures having both specific 
and nonspecific uptake of [123I] FP-CIT, respectively. 
This ROI template was also positioned on the reference 
SPECT section and adjusted on both striatal and occipi-
tal cortex. Moreover, striatal ROIs were also segmented 
into their anterior (caudate nucleus) and posterior (puta-
men) portions. Specific striatal dopamine uptake trans-
porter (DAT) binding of [123I] FP-CIT was calculated in 
the whole striatum, putamen and caudate nucleus using 
the formula: 
We also calculated putamen/caudate ratios for each 
subject. All patients underwent [18] F-Fluoro-2-deoxy-
glucose positron emission tomography scanning (FDG-
PET) at rest, after intravenous injection of 170 MBq. Each 
acquisition included a computed tomography (CT) trans-
mission scan of the head (50mAs lasting 16 s) followed by 
a three-dimensional (3D) static emission of 15 min using 
a Biograph Truepoint 64 PET/CT scanner (Siemens). 
PET sections were reconstructed using an iterative algo-
rithm (OS-EM), corrected for scatter and for attenuation, 
using density coefficients derived from the low dose CT 
scan of the head obtained with the same scanner, with the 
proprietary software. Images were reconstructed in the 
form of transaxial images of 128 × 128 pixels of 2 mm, 
using an iterative algorithm, ordered-subset expectation 
maximization (OSEM). The resolution of the PET system 
was 4–5 mm FWHM.
Biomechanical evaluation
Biomechanical evaluation was assessed at baseline and at 
six and 12  months after cell administration. Equipment 
and settings were previously described [26]. For this 
study in particular, two specific sets of parameters, one 
for standing and one for gait initiation, were automati-
cally extracted by means of ad hoc algorithms. For stand-
ing, we measured the center of pressure (CoP) mean 
velocity and spatial displacement [27–31]. To exam-
ine gait initiation we focused on anticipatory postural 
[(mean counts in specific ROI)
−(mean counts in occipital ROI)]
/(mean counts in occipital ROI).
adjustment [26, 32] (i.e. imbalance and unloading phases) 
and measured the following parameters: (1) the duration 
of both phases, (2) the antero-posterior (AP) and medio-
lateral (ML) shift and velocity of the CoP, (3) the CoP 
mean length and velocity. Finally, we also measured the 
(4) length and (5) velocity of the first step. Spatial param-
eters were normalized on the basis of body height (%BH).
Cell administration
The median cell dose was 1.7 (1.2–2.0)  ×  10E6 MSC/
kg of body weight. One single administration was per-
formed for each patient. Before cell administration, the 
patient underwent neuroleptoanalgesia and was moni-
tored by an anaesthetist. MSC were administered by 
intra-arterial route [33], with modifications according to 
local equipment and local standards. Briefly: with Seld-
inger technique, catheterization was carried out via the 
right common femoral artery (or the left one in the event 
of difficulty in achieving arterial access) using a 6F Ulti-
mum EV (St Jude Medical, MN, USA) introducer and a 
5F Hinck or Simmons (Terumo Europe NV, Leuven, Bel-
gium) diagnostic catheter. An angiographic study of the 
cervical and intracranial arteries was performed, with 
the support of an 0.035  in., 150  cm long hydrophilic 
guide (Terumo Europe NV, Leuven, Belgium). Subse-
quently, with or without an exchange manoeuvre, using 
a 260 cm exchange wire Easykit 0.35″ or 0.38″ (ab medica 
s.p.a., Lainate (MI), Italy), a 90 cm 6F Envoy XB guiding 
catheter (Miami Lakes, FL, USA) was used, after intrave-
nous administration of heparin sodium (3000–5000  IU 
according to body mass) to reduce the risk of thrombo-
embolism. The guiding catheter, flushed with heparin-
ised saline, was positioned at the origin of both internal 
carotid arteries and at the origin of the widest vertebral 
artery. Once the guiding catheter was in place, a Rebar 
027 (130 or 145 cm) or Rebar 018 (153 cm) microcathe-
ter (ev3/Covidien, Irvine, CA, USA), steered by a 205 cm 
Transend EX 0.014 (Boston Scientific, Natick, MA, USA), 
was moved forward and upward into the internal carotid 
arteries just above the origin of the ophthalmic arteries 
and into the basilar artery. The MSC were then injected 
into the various districts, through the microcatheter, 
using a pump at 70 mL/h. The catheter was flushed peri-
odically with heparinised normal saline solution.
Results
Five patients were included and treated in the study. 
Nine were pre-screened and seven tested positive in 
the validation study with a good rate of MSC expan-
sion. As expected, in view of the severity of the disease, 
another two patients were not enrolled because one 
died before MSC administration and the other one rap-
idly worsened and was no longer eligible at the time of 
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MSC treatment. Clinical and imaging data are listed in 
Tables 1 and 2, respectively. All the patients were alive 
at 12 months, except one, who died 9 months after cell 
administration for causes not related to the treatment: 
she fell accidentally before the six-month assessment 
and was not able to come for the follow-up visits. Also 
the last patient did not come for the 6  month assess-
ment due to hospitalization for rehabilitation. There-
fore the latest follow-up point was 12 months for three 
patients and 3  months for the remaining two. All the 
evaluable patients had stable UPDRS scores at the last 
follow-up. The PSP-RS also demonstrated disease stabi-
lization at 6 and 12 months in all the evaluable patients, 
except one (PSP08). Another important positive effect 
was recorded by H&Y staging, which remained stable 
over time. The results of biomechanical evaluation are 
shown in Table 3. 
Patient clinical presentation
Case I (PSP01)
The first patient enrolled was a male who noticed motor 
impairment in his right arm at the age of 52. Diagnosis 
of PSP was made two years after the onset of symptoms, 
when gait difficulty, instability with falls, dysarthria, dys-
phagia and vertical gaze appeared and motor symptoms 
worsened. Brain MRI and ECD SPECT were also com-
patible with PSP. Five years later he needed a walker due 
to postural instability and backward falls. Dysarthria and 
dysphagia worsened over time. The patient was enrolled 
in this study after 8 years of disease. At the time of enroll-
ment, neuropsychological evaluation was in the normal 
range with the exception of mild depression, irritability 
and anxiety. Brain MRI showed slight subcortical, fronto-
parietal and mesencephalic atrophy. FDG PET showed 
bilateral hypometabolism in the frontal superior gyrus, 
Table 1 Patients’ description
Demographical data, cell dose, baseline and follow-up neuropsycological assessments by mini-mental state evaluation (MMSE) and clinical scoring using three 
different scales
For UPDRS and PSP-RS the values are reports as absolute value and percentage of variation from baseline (in brackets)
H&Y Hoehn-Yahr stage, UPDRS III Unified Parkinson’s Disease Rating Scale part III, PSP-RS PSP rating score, na not available
Case 1 (PSP01) Case 2 (PSP02) Case 3 (PSP06) Case 4 (PSP08) Case 5 (PSP09)
Demographic data and cell dose
 Gender M F F F F
 Age (years) 60 66 65 65 68
 Disease duration (years) 8 7 4 6 5
 Cell dose (×106/kg) 1.4 1.7 2 1.8 1.2
MMSE
 Baseline 27.49 28.27 25.49 24.27 25.53
 1-month 27.49 25.27 26.49 24.27 28.53
 12-month 26.49 25.03 na 21.27 na
H&Y
 Baseline 4/5 4/5 4/5 4/5 4/5
 1-month 4/5 4/5 4/5 4/5 4/5
 3-month 4/5 4/5 4/5 4/5 4/5
 6-month 4/5 4/5 na 4/5 na
 12-month 4/5 4/5 na 4/5 na
UPDRS III
 Baseline 47 38 47 31 42
 1-month 45 (−4 %) 37 (−3 %) 36 (−23 %) 31 (0 %) 48 (+14 %)
 3-month 47 (0 %) 49 (+29 %) 48 (+2 %) 39 (+26 %) 48 (+14 %)
 6-month 45 (−4 %) 51 (+34 %) na 40 (+29 %) na
 12-month 47 (0 %) 47 (+24 %) na 40 (+29 %) na
PSP-RS
 Baseline 37 53 52 36 57
 1-month 41 (+11 %) 40 (−25 %) 46 (−12 %) 39 (+8 %) n.a.
 3-month 44 (+19 %) 39 (−26 %) 43 (−17 %) 46 (+28 %) 51 (−11 %)
 6-month 47 (+27 %) 63 (+19 %) na 52 (+44 %) na
 12-month 47 (+27 %) 57 (+8 %) na 53 (+47 %) na
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anterior cingulate, caudatus and midbrain. Severe reduc-
tion in dopamine transporter binding in the striatum 
was evident at FP-CIT SPECT. Biomechanical evaluation 
revealed normal measurements for standing, but several 
alterations of gait initiation.
Case II (PSP02)
Female, at the age of 63 she began to complain of rigid-
ity, bradykinesia and unstable gait. She complained above 
all of neck pain that did not respond to any symptomatic 
therapy. Two years after the appearance of the first motor 
symptoms, clinical symptoms, brain MRI and FP-CIT 
SPECT supported the diagnosis of PSP. One year later 
she was still able to walk without assistance, but falls were 
more frequent and mild dystonic posture in the left leg was 
evident. The patient took part in the study after 7 years of 
disease. Neuropsychological evaluation was in the normal 
range with the exception of a slight deficit in long-term 
verbal memory. FDG PET showed hypometabolism in the 
polar temporal area, and in the ponto-mesencephalic and 
midbrain areas. Severe reduction in dopamine transporter 
binding in the striatum was evident. The patient was 
unable to perform biomechanical analysis of movement 
because of apraxia involving her right leg.
Case III (PSP06)
The story of the third patient began at the age of 62 when 
she first noticed bradykinesia and mild depression. A 
few months later postural instability and falls appeared. 
Four years later she complained mainly of postural insta-
bility and difficulty in eye movements. The patient took 
part in the study after 4 years of disease. At the time of 
enrollment neuropsychological evaluations revealed mild 
depression and mild deficit in executive functions and 
visual-spatial abilities. Brain MRI showed mild ence-
phalic and cerebellar cortical atrophy, and severe mesen-
cephalic atrophy. Before MSC treatment, we were able to 
perform biomechanical measurement of standing only. 
In comparison to healthy controls, we found high values 
of ML displacement of CoP and high CoP velocity, thus 
suggesting great difficulties in maintaining the upright 
position.
Case IV (PSP08)
Female, at 61  years of age she complained of instability 
and occasional falls. Diagnosis of PSP was made 4 years 
later. The patient took part in the study after 6  years of 
disease. Neuropsychological evaluation showed deficit 
in cognitive and executive functions, visual-construction 
abilities and selective attention. Depression and anxiety 
were evident. Brain MRI showed fronto-parietal cor-
tical atrophy, severe mesencephalic atrophy and mild 
cortical cerebellum atrophy. FDG PET showed severe 
hypometabolism in brainstem, moderate bilateral hypo-
metabolism in the parietal lobe and slight bilateral hyper-
metabolism in fronto-orbital regions. Dopaminergic 
striatal innervation loss was remarkable bilaterally. Bio-
mechanical evaluation performed before MSC infusion 
revealed only increased antero-posterior (AP) displace-
ment of CoP, which was greater than normal values in the 
standing position. However, almost all parameters related 
to gait initiation were altered.
Case V (PSP09)
Female, at the age of 63 she began to complain of pos-
tural instability and retropulsion. Four years later, she 
presented with mild movement impairment, instability, 
akinesia at night, mild dysphagia, and irritability. She also 
Table 2 SPECT and PET data
Specific striatal dopamine uptake transporter (DAT) binding of [123 I] FP-CIT, 
calculated in the whole striatum, putamen and caudate nucleus using the 
formula: 
[
(mean counts in specific ROI)− (mean counts in occipital ROI)
]
/
(mean counts in occipital ROI)
Baseline 12-month
Case 1 (PSP01) R striatum = 0.16 R striatum = 0.19
L striatum = 0.14 L striatum = 0.16
R caudate nucleus = 0.27 R caudate nucleus = 0.10
L caudate nucleus = 0.17 L caudate nucleus = 0.23
R putamen = 0.08 R putamen = 0.27
L putamen = 0.10 L putamen = 0.09
Case 2 (PSP02) R striatum = 0.49 R striatum = 0.34
L striatum = 0.35 L striatum = 0.21
R caudate nucleus = 0.59 R caudate nucleus = 0.48
L caudate nucleus = 0.39 L caudate nucleus = 0.33
R putamen = 0.42 R putamen = 0.1
L putamen = 0.35 L putamen = 0.01
Case 3 (PSP06) R striatum = 0.42 na
L striatum = 0.60
R caudate nucleus = 0.54
L caudate nucleus = 0.73
R putamen = 0.30
L putamen = 0.43
Case 4 (PSP08) R striatum = 1.00 R striatum = 0.61
L striatum = 1.15 L striatum = 0.72
R caudate nucleus = 1.30 R caudate nucleus = 0.67
L caudate nucleus = 1.46 L caudate nucleus = 0.72
R putamen = 0.79 R putamen = 0.55
L putamen = 0.86 L putamen = 0.65
Case 5 (PSP09) R striatum = 0.37 na
L striatum = 0.46
R caudate nucleus = 0.37
L caudate nucleus = 0.55
R putamen = 0.36
L putamen = 0.39
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Table 3 Biomechanical evaluation
(A) Normal values Case 1 (PSP01) Case 4 (PSP08)
(10°–90° percentile) Basal 6-month 12-month Basal 6-month 12-month
Standing
Ellipse area (mm2) %BA 0.06–0.66 0.08 0.33 0.18 0.34 0.55 0.18
Ellipse eccentricity 0.62–0.97 0.97 0.92 0.8 0.98 0.99 0.80
Axis length AP avg. (mm) %FL 0.20–8.86 3.05 4.21 3.35 9.27a 3.73 3.35
Axis length ML avg. (mm) %FL 0.12–3.66 2.37 2.35 1.21 0.12 1.54 1.21
Sway path (CoP) velocity avg. (mm/s) 6.5–18.11 7.26 7.62 6.57 9.41 19.43 6.58
Gait initiation
Imbalance phase
 Duration (s) 0.29–0.53 0.61a 0.84a 0.49 0.36 0.43 0.36
 AP avg. (mm) %FL 9.58–17.26 0.86a 2.14a 1.04a 4.48a 1.73a 0.32a
 AP vel. avg. (mm/s) 58.83–112.61 3.32a 13.68a 2.78a 22.33a 8.31a 1.01a
 ML avg. (mm) %FL 4.6–19.21 5.13 6.61 3.55a 4.12a 3.18a 3.78a
 ML vel. avg. (mm/s) 32.15–144.77 17.55a 43.53 23.1 24.78a 15.71a 27.22a
 Sway path (CoP) velocity avg. (mm/s) 96.34–178.07 19.38a 46.99a 26.25a 36.17a 29.45a 28.74a
 Sway path (CoP) length (mm) 36.73–63.60 14.29a 18.75a 11.69a 16.04a 11.12a 10.35a
Unloading phase
 Duration (s) 0.23–0.47 1.45a 0.83a 1.29a 1.09a 0.76a 1.36a
 AP avg. (mm) %FL 3.9–14.44 7.94 8.73 8.79 11.48 12.28 8.21
 AP vel. avg. (mm/s) 7.1–92.4 11.31 61.16 14.38 19.00a 37.42 10.71
 ML avg. (mm) %FL 29.15–61.84 33.1 43.08 36.68 54.34 45.05 37.47
 ML vel. avg. (mm/s) 265.14–481.64 78.31a 143.24a 85.81a 150.63a 151.28a 85.31a
 Sway path (CoP) velocity avg. (mm/s) 269.18–510.98 108.73a 150.99a 95.58a 160.86a 163.10a 95.63a
 Sway path (CoP) length (mm) 79.6–169.24 99.07 119.54 111.61 138.33 113.69 115.61
Step phase
 First step peak velocity (mm/s) 1475.4–1874.1 486.52a 783.05a 604.83a 714.70a 498.68a 566.64a
 First step length (%BH) 26.27–33.63 21.04a 24.44a 17.08a 14.34a 8.21a 16.92a
(B) Normal values Case 3 (PSP06) Case 5 (PSP09)
(10°–90° percentile) Basal Basal
Standing
Ellipse area (mm2) %BA 0.06–0.66 0.49 329.68a
Ellipse eccentricity 0.62–0.97 0.98 0.91
Axis length AP avg. (mm) %FL 0.20–8.86 6.78 5.16
Axis length ML avg. (mm) %FL 0.12–3.66 4.31a 4.13a
Sway path (CoP) velocity avg. (mm/s) 6.5–18.11 133.81a 12.69
Gait initiation
Imbalance phase
 Duration (s) 0.29–0.53 ne 0.77a
 AP avg. (mm) %FL 9.58–17.26 ne 6.01
 AP vel. avg. (mm/s) 58.83–112.61 ne 16.70a
 ML avg. (mm) %FL 4.6–19.21 ne 5.15
 ML vel. avg. (mm/s) 32.15–144.77 ne 20.02a
 Sway path (CoP) velocity avg. (mm/s) 96.34–178.07 ne 31.29a
 Sway path (CoP) length (mm) 36.73–63.60 ne 22.06a
Unloading phase
 Duration (s) 0.23–0.47 ne 1.00a
 AP avg. (mm) %FL 3.9–14.44 ne 5.63
 AP vel. avg. (mm/s) 7.1–92.4 ne 8.63
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reported hypothyroidism and had had left knee replace-
ment. Diagnosis of PSP was made and the patient took 
part in the study after 5 years of disease. At the time of 
enrollment, brain MRI showed mild cortical, and severe 
subcortical and mesencephalic atrophy. Cerebellar corti-
cal atrophy was also evident. FDG PET showed bilateral 
hypometabolism in frontal area, right insula and tempo-
ral area; mesencephalic and cerebellar hypometabolism 
was also evident. Neuropsychological evaluation showed 
normal cognition, but deficits in executive and atten-
tional functions, and in visual-spatial ability. Biomechani-
cal measurements during standing showed high values of 
CoP sway path, in particular in medio-lateral (ML) direc-
tion. Regarding gait initiation, the patient showed altered 
values of almost all parameters.
BM aspiration, cell administration and short term (24-hour) 
follow-up
All the patients underwent BM aspiration with no side 
effects. Cell administration was well tolerated in all 
patients. Neurological assessment remained stable after 
MSC administration in all patients, except one (Case 
V), in whom transient left hemiparesis was recorded. 
Also brain MRI performed 24 h after cell administration 
showed spotty ischemic lesions in all the patients (Fig. 1), 
while ischemic alterations in the posterior segment of the 
left inferior peduncle of the cerebellum and in the right 
mesencephalon were found in the last patient.
Clinical assessment
Case I (PSP01)
One month after MSC treatment the patient and car-
egiver reported improvement in balance and gait, and a 
slight improvement in dysphagia. Neuropsychological 
evaluation showed no cognitive changes with regards to 
pre-treatment values and an improvement in mood.
At three, six and 12  month follow-up, clinical condi-
tions were stable and the improvement in balance and 
gait persisted. Neuropsychological evaluation remained 
unchanged, with the exception (at 1 year) of mild daytime 
somnolence and worsening in executive and long-term 
memory (at the lower limit of the normal range). Mood 
was always in the normal range.
Biomechanical measurements performed 6 and 
12 months after MSC infusion showed a global improve-
ment in balance and gait initiation. In particular, the 
duration of the imbalance phase and the relative ML 
velocity of CoP normalized after MSC infusion.
Case II (PSP02)
At 1  month follow-up there were subjective improve-
ments in stability, eye mobility, tone of voice and signifi-
cant reduction in painful neck rigidity. The patient and 
her caregiver noticed an improvement in gait, although 
assistance was still necessary. Motor function remained 
stable for six  months. Thereafter the patient and her 
caregivers noticed worsening of apraxia in the right leg 
resulting in instability and gait difficulty. Neck pain was 
still present, but somewhat milder than before MSC 
administration. Neuropsychological evaluation described 
worsening of executive function and long-term verbal 
memory.
Brain MRI showed increased atrophy in the mesen-
cephalon, but no modification in other areas.
FDG PET findings were almost unchanged, with mild 
worsening in the prefrontal cortical area. The striatal 
density of dopamine transporters also worsened.
Case III (PSP06)
At one-month follow-up the patient, and her caregivers, 
reported improvement in gait and stability. Although 
she was not self-sufficient, she needed less assistance 
(A) Patients with complete follow-up; (B) patients with only basal evaluation. Case 2 (PSP 02) was not evaluable (ne) because of dystonia
For abbreviations: see text
a  Patient’s parameters outside the range between 10 and 90° percentile of healthy control subjects’ values
Table 3 continued
(B) Normal values Case 3 (PSP06) Case 5 (PSP09)
(10°–90° percentile) Basal Basal
 ML avg. (mm) %FL 29.15–61.84 ne 54.85
 ML vel. avg. (mm/s) 265.14–481.64 ne 129.37a
 Sway path (CoP) velocity avg. (mm/s) 269.18–510.98 ne 132.25a
 Sway path (CoP) length (mm) 79.6–169.24 ne 129.71
Step Phase
 First step peak velocity (mm/s) 1475.4–1874.1 ne 596.99a
 First step length (%BH) 26.27–33.63 ne 12.78a
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during daily activities, had improvement in ocular 
mobility mostly downward and reduction in photopho-
bia. She also reported improvement in constipation. No 
changes for dysarthria and dysphagia were recorded. The 
improvement persisted at the 3 month follow-up visit.
Shortly before the 6  month follow-up evaluation, 
the patient fell and fractured her right foot. No biome-
chanical evaluation of posture and gait was thereafter 
attempted. Following this accident her clinical condi-
tions worsened, the patient experienced depression and 
she refused food and drink. Renal function worsened and 
9  months after MSC treatment the patient died in the 
emergency care unit due to cardiac arrest.
Case IV (PSP08)
One month after MSC administration neuropsychologi-
cal evaluation showed global cognitive functions in the 
normal range, an increase in anxiety and depression. 
Her principal complaint was visual difficulty that was 
already present at the beginning of the disease. Three 
months after, improvement in global cognitive func-
tions and increase in MMSE (from 24/26 to 27/30) was 
recorded. Nevertheless, depression and anxiety remained 
unchanged. Visual disturbances were still bothersome 
for the patient. Six months after MSC therapy subjec-
tive and objective evaluations were unchanged, the main 
complaint reported by the patient being ocular distur-
bances with photophobia and lacrimation, as at the onset 
of the disease. One year after MSC therapy, the clini-
cal conditions of the patient were stable. FDG PET was 
unchanged, whereas FP-CIT SPECT showed a greater 
reduction in dopamine transporter binding in the stria-
tum. A biomechanical evaluation of posture and gait 
initiation was performed 6 and 12  months after MSC 
infusion and showed global worsening of maintenance of 
upright posture and walking planning.
Case V (PSP09)
In the last patient, sensory-motor facio-brachial-crural 
left hemisyndrome appeared 12  h after MSC adminis-
tration. After 24 h hyposthenia of upper left arm, hemi-
facial paresis with severe dysarthria and dysphagia 
persisted. Brain MRI, performed 24  h after the proce-
dure, showed ischemic alterations in the posterior seg-
ment of the left inferior peduncle of the cerebellum and 
in the right mesencephalon. During the following weeks, 
the neurological syndrome gradually improved with per-
sistence of minor deficits (i.e. dysarthria, dysphagia and 
mild hyposthenia of the left arm). At 3 month-follow-up 
no sensory-motor deficits in the left arm were recorded. 
The patient did not attend the next follow-up visits, but 
information gathered on the telephone confirmed pos-
tural instability, whereas dysarthria was stable.
Discussion
The “Holy Grail” for cellular therapy of degenerative 
disorders is neural cell replacement. However, despite 
initial encouraging results with fetal dopaminergic neu-
ron transplantation [34], the goal is still far away and, 
up to now, no feasible, safe and effective cell therapy is 
Fig. 1 RMN study: representative figure of the RMN performed before a and 24 h after b cell administration. In b the arrows indicate several spotty 
lesions
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available. On the other hand, there are numerous severe 
and progressive neurodegenerative disorders, which 
do not respond to any available therapy, symptomatic 
therapy included, and invariably lead to disabilities with 
heavy individual and societal consequences. In consid-
eration of these still unmet clinical needs, major efforts 
are to be made to find innovative approaches that can 
provide novel tools to contrast disease progression and, 
at the very least, reduce the consequences of progressive 
neural cell loss.
With this aim in mind, we designed a phase I study, to 
test the safety of MSC administration in patients affected 
by PSP and to collect preliminary data on its efficacy. 
Herein we describe the evidence that we have gathered 
through first-in-man experience in five patients treated in 
the open phase of our trial and the findings during a one-
year follow-up. To our knowledge, this is the first clini-
cal trial testing autologous bone marrow MSC in PSP. 
The subjects in our trial were patients with rapidly pro-
gressing, severe disease for which there are no therapeu-
tic options. Therefore, even though this phase I trial was 
not designed to test the efficacy of MSC, the stabilization 
of the rating scale scores after the intervention and dur-
ing one-year follow-up is of utmost importance. Actu-
ally, in this study all subjects were evaluated by means 
of the best available rating scales for the assessment of 
motor function in patients with Parkinsonism (i.e. PSP-
RS, UPDRS motor score and H&Y staging), as well as by 
biomechanical evaluation of gait and posture at differ-
ent time points. We report that all the patients at the last 
follow-up had stable clinical assessment scores related to 
at least two validated scales and one patient maintained 
this stabilization for 1  year. Regarding the biomechani-
cal evaluation, as expected, it confirmed the presence 
of great difficulties in balance and planning of gait [35] 
in all patients. Despite being not applicable to severely 
impaired patients, such a biomechanical evaluation 
proved to be a reliable method to investigate motor and 
postural capabilities in PSP patients. We were also able 
to describe mild improvement in one subject (PSP01) 
12 months after MSC infusion.
Regarding safety, it must not be left unsaid that intra-
arterial administration of MSC is associated with impor-
tant safety concerns because of the intrinsic risk of 
microembolization, which, in our experience was invari-
ably present in all the treated patients. This risk had been 
already reported by Lee and co-workers, who treated 
patients affected by multiple system atrophy [36] and 
seems to depend, to some extent at least, on the intrin-
sic infusion technique. It was indeed present also in the 
placebo group and at a higher frequency compared to 
the treated group (35 vs 29 %). Other factors that may be 
involved in microembolization during MSC intrarterial 
administration are cell size and type [37] and infusion 
velocity [38, 39]. In consideration of this risk and of its 
determinants, a stringent and accurate follow up was 
implemented, including frequent clinical assessments 
and the execution of MRI before and 24  h after inter-
vention. An interdisciplinary evaluation of each single 
patient was performed jointly by the neurologist, the 
interventional radiologist and the anesthesiologist. In our 
study all the patients were alive 1 year after cell adminis-
tration, except one, who died of the consequences of an 
accidental fall. To correctly interpret the significance of 
these findings, we analyzed the historical cohort of 455 
PSP patients followed by our Center over the last years. 
In a subgroup of subjects (n = 118) with the same char-
acteristics as the patients enrolled in the study, only 24 % 
of them were followed up for at least 1  year, the main 
causes of unavailability being death or severe disease pro-
gression (personal data, not shown). This makes the sur-
vival rate in our trial extremely significant.
Conclusions
Despite their preliminary nature, these first-in-man 
results with PSP patients are encouraging and can be eas-
ily transferred to several other neurodegenerative disor-
ders. The approach followed in our study is, in fact, not 
to replace diseased neurons (“replacement” cell therapy) 
but to reduce the consequences and the rate of neural cell 
deterioration by using MSC as a medication. The inten-
tion is to exploit their well-known biological function in 
preserving cell homeostasis and maintaining a healthy 
microenvironment (“rescue” cell therapy). Due to the 
complexity and the specialization of the different types 
of neural cells, a specific replacement cell therapy should 
be developed for any single disease, while the “rescue” 
cell therapy may be suitable for many types of neurode-
generative disorders. For all these reasons the experi-
ence herein reported may be of general interest as a way 
to find suitable therapy for orphan neurologic disorders. 
Moreover, it paves the way to the next phase-II rand-
omized, double-blind, placebo-controlled trial that may 
provide more valuable insights into the potential efficacy 
of MSC for neurodegenerative disorders.
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